NSAA

(redirected from Nonsteroidal Antiandrogen)
AcronymDefinition
NSAANational Ski Areas Association
NSAANebraska School Activities Association
NSAANorth Shore Art Association (Gloucester, MA)
NSAANational Surgical Assistant Association
NSAANational Student Assistance Association
NSAANonsteroidal Antiandrogen
NSAANational Speakers Association Australia
NSAANorwegian Singers Association of America
NSAANational Scenic Area Act (Washington)
NSAANational Survey of African American Mental Health
NSAANational Sports Association of America (Columbia, TN)
References in periodicals archive ?
Androgen deprivation therapy (ADT) with gonadotropin-releasing hormone analogues combined with or without nonsteroidal antiandrogens is standard treatment for advanced prostate cancer.
The latter is characterized by worsening of symptoms and is caused by the acute increase in serum testosterone concertrations.[29] For example, 3% to 17% of patients receiving an LHRH analog have reported worsening bone pain during the first week of treatment.[25,27,29-32 This flare reaction can be ameliorated by prior and con-current therapy with DES or flutamide (a nonsteroidal antiandrogen), which blocks adrental androgen production.[30,31] It is not know how long flare blockade treatment needs to be administered, but as several deaths have been reported coincident with unblocked flare reactions, use of a blocking agent should be considered.[32]
The nonsteroidal antiandrogen flutamide has been approved for use in combination with LHRH analogs in the treatment of prostate cancer.
The present results are placed in the context of structure-activity knowledge derived from previous modeling studies as well as studies aimed toward designing nonsteroidal antiandrogen pharmaceuticals.
SAR evidence gathered from previous study of an extensive series of nonsteroidal antiandrogens (Tucker et al.
-- A once-daily dosage of the nonsteroidal antiandrogen bicalutamide decreased the risk of prostate cancer progression by 57%, Dr.
Nonsteroidal antiandrogen therapy would increase survival by 7.4 years, and diethylstilbestrol would increase survival by 6.9 years.
Nonsteroidal antiandrogens and luteinizing hormone-releasing hormone (LHRH) analogues are mostly used for metastatic prostate cancer.